Pharmalittle:Vaxcyte 肺炎球菌疫苗 VAX-31 III 期达主要终点,FDA 延长 Novo Nordisk 血友病药 denecimig 审评
STAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and more
Vaxcyte 的实验性肺炎球菌疫苗 VAX-31 在 III 期试验中达到主要终点,该疫苗覆盖 31 种血清型,公司仍需完成两项试验才能申报上市。FDA 因生产设施整改延长了 Novo Nordisk 血友病 A 药物 denecimig 的审评,该药于 2025 年 9 月提交申请,原预期 2026 年第三季度获得 FDA 决定。
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating. Now, though, that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance. You knew this would happen, yes? After all, the world — such as it is — continues to spin. So to nudge it in a better direction, we are relying, as always, on a cuppa stimulation. Our choice today is blueberry hibiscus. Of course, you are welcome to join us. Meanwhile, here are a few items of interest. Best of luck accomplishing your goals, and we hope you conquer the world. And, of course, do keep in touch. …
Vaxcyte disclosed that its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up a competition with Pfizer and Merck, STAT writes. Vaxcyte’s shot, VAX-31, is designed to protect against 31 serotypes, or strains, of bacteria that can cause pneumococcal disease, including pneumonia, compared to 20 strains for Pfizer’s Prevnar and 21 strains for Merck’s Capvaxive. The company needs two more trials to deliver results before it can file for approval: a study looking at VAX-31 administered alongside an influenza vaccine and a study in adults who previously received a different pneumococcal shot.
The U.S. Food and Drug Administration has extended its review of an experimental hemophilia A drug from Novo Nordisk due to ongoing remediation work at a manufacturing facility, Reuters notes. Novo had submitted the application for the drug, called denecimig, in September 2025 and was expecting an FDA decision in the third quarter of 2026. While the regulator has not yet set a new timeline for its decision, Novo said the FDA did not raise any concerns regarding the safety or effectiveness data from the drug’s clinical trials. Novo added that the manufacturing site issues do not impact any of its other medicines currently on the market.
来源:STAT Pharma 医药频道 · statnews.com